17 days ago
IBRX
AnalystsJoseph CatanzaroJoseph Catanzaro's Stock Forecasts
AnalystsJoseph Catanzaro
Analyst Ranking
Bottom 34%
#3452 out of 5186 analysts
Average Return
-0.01%
Win Rate
34%34 out of 100
Risk vs Reward
Poor
Good
Joseph Catanzaro's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cytomx Therapeutics IncCTMX | +764.69% | $0.61 | $5.24 | 2025-04-13 - 2026-02-05 | Strong Buy |
Immunomedics IncIMMU | +235.60% | $26.18 | $87.86 | 2020-04-22 - 2020-10-22 | Strong Buy |
Cytomx Therapeutics IncCTMX | +162.00% | $2.00 | $5.24 | 2025-05-14 - 2026-02-05 | Strong Buy |
Ocular Therapeutix IncOCUL | +150.14% | $7.40 | $18.51 | 2020-03-04 - 2021-03-05 | Strong Buy |
Halozyme Therapeutics IncHALO | +145.03% | $19.97 | $48.92 | 2020-02-04 - 2021-02-05 | Strong Buy |
Joseph Catanzaro Analyst Color
Get additional color on Joseph Catanzaro's coverage of popular stocks
2 years ago
IBRX
2 years ago
IOVA
Joseph Catanzaro's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Nurix Therapeutics IncNRIX | 5 | Strong Buy | $35.00 | +119.44% | Maintains | 8 days ago |
Immunitybio IncIBRX | 7 | Strong Buy | $7.00 | +24.11% | Maintains | 17 days ago |
Cytomx Therapeutics IncCTMX | 5 | Strong Buy | $10.00 | +90.84% | Maintains | 17 days ago |
Revolution Medicines IncRVMD | 4 | Buy | $143.00 | +48.73% | Maintains | 24 days ago |
Avalo Therapeutics IncAVTX | 1 | Buy | $39.00 | +196.58% | Initiates Coverage On | 2 months ago |
Upstream Bio IncUPB | 1 | Buy | $51.00 | +96.15% | Initiates Coverage On | 2 months ago |
Bicara Therapeutics IncBCAX | 1 | Hold | $18.00 | +19.21% | Initiates Coverage On | 2 months ago |
Spyre Therapeutics IncSYRE | 1 | Buy | $53.00 | +60.90% | Initiates Coverage On | 2 months ago |
Kymera Therapeutics IncKYMR | 2 | Buy | $120.00 | +58.02% | Maintains | 2 months ago |
Celldex Therapeutics IncCLDX | 1 | Buy | $48.00 | +112.58% | Initiates Coverage On | 4 months ago |
Apogee Therapeutics IncAPGE | 1 | Buy | $105.00 | +69.00% | Initiates Coverage On | 4 months ago |
Iovance Biotherapeutics IncIOVA | 9 | Hold | $6.00 | +154.24% | Maintains | a year ago |
Schrodinger IncSDGR | 3 | Strong Buy | $45.00 | +247.76% | Maintains | a year ago |
Merus NvMRUS | 1 | Strong Buy | $84.00 | -6.67% | Initiates Coverage On | a year ago |
Gilead Sciences IncGILD | 5 | Strong Buy | $110.00 | -26.36% | Maintains | a year ago |
Exelixis IncEXEL | 4 | Strong Buy | $38.00 | -10.31% | Maintains | a year ago |
Keros Therapeutics IncKROS | 3 | Strong Buy | $15.00 | N/A | Maintains | a year ago |
Halozyme Therapeutics IncHALO | 6 | Hold | $53.00 | N/A | Maintains | a year ago |
Cardiff Oncology IncCRDF | 4 | Strong Buy | $10.00 | N/A | Maintains | a year ago |
Essa Pharma IncEPIX | 2 | Hold | $2.00 | N/A | Downgrades | a year ago |
Biomea Fusion IncBMEA | 5 | Strong Buy | $19.00 | N/A | Maintains | a year ago |
Immatics NvIMTX | 1 | Strong Buy | $19.00 | N/A | Initiates Coverage On | a year ago |
Black Diamond Therapeutics IncBDTX | 3 | Strong Buy | $15.00 | N/A | Maintains | a year ago |
Whitehawk Therapeutics IncWHWK | 3 | Hold | $1.75 | N/A | Downgrades | a year ago |
Turnstone Biologics CorpTSBX | 2 | Strong Buy | $3.75 | N/A | Maintains | a year ago |
Lenz Therapeutics IncLENZ | 2 | Strong Buy | $36.00 | N/A | Maintains | a year ago |
Day One Biopharmaceuticals IncDAWN | 5 | Strong Buy | $40.00 | N/A | Maintains | 2 years ago |
Ocular Therapeutix IncOCUL | 4 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
Context Therapeutics IncCNTX | 1 | Strong Buy | $4.50 | N/A | Initiates Coverage On | 2 years ago |
Acrivon Therapeutics IncACRV | 2 | Strong Buy | $30.00 | N/A | Maintains | 2 years ago |
Boundless Bio IncBOLD | 1 | Strong Buy | $20.00 | N/A | Initiates Coverage On | 2 years ago |
Achilles Therapeutics PLCACHL | 3 | Hold | $2.00 | N/A | Downgrades | 2 years ago |
Novabridge BiosciencesNBP | 4 | Strong Buy | $10.00 | N/A | Maintains | 2 years ago |
Tango Therapeutics IncTNGX | 1 | Strong Buy | $18.00 | N/A | Initiates Coverage On | 2 years ago |
Gracell Biotechnologies IncGRCL | 1 | Hold | $10.00 | N/A | Downgrades | 2 years ago |
Immunogen IncIMGN | 2 | Hold | $31.00 | N/A | Downgrades | 2 years ago |
Repare Therapeutics IncRPTX | 3 | Strong Buy | $25.00 | N/A | Maintains | 2 years ago |
Mirati Therapeutics IncMRTX | 1 | Hold | $58.00 | N/A | Downgrades | 2 years ago |
Rain Oncology IncRAIN2 | 2 | Hold | $1.75 | N/A | Downgrades | 3 years ago |
Catalyst Pharmaceuticals IncCPRX | 1 | Strong Buy | $20.00 | N/A | Maintains | 3 years ago |
Oyster Point Pharma IncOYST | 1 | Hold | $11.00 | N/A | Downgrades | 3 years ago |
Harpoon Therapeutics IncHARP | 2 | Strong Buy | $70.00 | N/A | Maintains | 3 years ago |
Connect Biopharma Holdings LtdCNTB | 1 | Hold | $1.50 | N/A | Downgrades | 4 years ago |
Sensei Biotherapeutics IncSNSE | 2 | Strong Buy | $200.00 | N/A | Maintains | 4 years ago |
Neurogene IncNGNE | 1 | Strong Buy | $125.00 | N/A | Maintains | 4 years ago |
Figs IncFIGS | 1 | Strong Buy | $35.00 | N/A | Initiates Coverage On | 5 years ago |
Marker Therapeutics IncMRKR | 1 | Strong Buy | $60.00 | N/A | Initiates Coverage On | 5 years ago |
Seagen IncSGEN | 2 | Hold | $170.00 | N/A | Maintains | 5 years ago |
Immunomedics IncIMMU | 1 | Strong Buy | $40.00 | N/A | Maintains | 6 years ago |
Xbiotech IncXBIT | 2 | Strong Buy | $18.00 | N/A | Maintains | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.